DUBLIN Jecure Therapeutics Inc. raised $20 million in series A funding for the discovery and development of therapeutics to treat non-alcoholic steatohepatitis (NASH) and liver fibrosis, based on new insights into the sterile inflammatory processes that drive the disease.
Scientific founder Ariel Feldstein, division chief of gastroenterology at University of California, San Diego School of Medicine, teamed up with proven drug hunters Jeffrey Stafford and James Veal. San Francisco-based Versant Ventures ponied up the cash.
"This is our fourth investment in the fibrosis space," Versant managing director Brad Bolzon told BioWorld Today.
It's also Versant's second bet on the abilities of Stafford and Veal to come up with molecules that whet the appetites of big pharma and big biotech. The duo have